The H3 TAR device received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) on June 4, 2019, and as a condition of that approval, this study is being conducted to provide long-term safety and effectiveness of the H3 TAR System among patients included in the Primary Safety and Effectiveness (PSE) Cohort (P1600361). This will be a Prospective, single-center, single arm study.
The Hintermann Series H3® (H3) prosthesis is a mobile bearing total ankle replacement (TAR) indicated for use as a non-cemented implant to replace a painful arthritic ankle joint due to primary osteoarthritis, post-traumatic osteoarthritis or arthritis secondary to inflammatory disease (e.g., rheumatoid arthritis, hemochromatosis, etc.). This will be a Prospective, single-center, single arm study. All living subjects who participated in the PSE cohort, regardless of whether or not the subject has had a revision/removal followed through the 10-year post-operation visit. 298 subjects were originally included in the PSE cohort. Through 10 years follow up. Based on the last surgery date, it is projected the study will be completed with the final 10-year follow-up visit to occur in December 2024. Patients will undergo clinical and radiographic evaluation at 5 and 10 years (+/- 90 days) post-operation. Performance Goals (PGs) will be constructed for the 10-year endpoint. As with the PGs used in the PMA study, these will be based on a prospectively defined, systematic meta-analysis of available published literature and registry data for the control (a legally marketed mobile bearing ankle). The details of the meta-analysis will be pre-specified in a protocol for this purpose. Both the protocol and the meta-analysis will be completed prior to the completion of the study.
Study Type
OBSERVATIONAL
Enrollment
298
The H3 includes a metal tibial component, a polyethylene sliding insert (PE inlay), and a metal talar component.
Kantonsspital Baselland
Bruderholz, Switzerland
AOFAS Score Measurement
The American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score is among will be used for measuring the outcome of treatment in patients who sustained a complex ankle or hindfoot injury. It will be measured at a minimum 10 years post-operation
Time frame: 10 Years
Survivorship Measurement
Survivorship (absence of removal/revisions to include polyethylene revision) will be recorded at 10 years from surgery
Time frame: 10 Years
Serious device-related adverse event Measurement
Percentage of subjects with a serious device-related adverse event, other than a revision or removal will be calculated at 10 years from surgery
Time frame: 10 Years
Reoperation, revisions or removals Measurement
Safety Reporting of the reoperation, revisions or removals of the Hintermann Ankle device will be reviewed and analyzed
Time frame: 10 Years
Serious Device-Related Adverse Events Measurement
Incidence, occurrence, and types of serious device-related adverse events will be reviewed and analyzed for subjects Nature, onset, duration, severity, relationship to the device, and relationship to the operative procedure and outcome of any adverse event will be measured.
Time frame: 10 Years
Device Explant Analysis Measurement
Any explanted devices / device components will be returned and handled for analysis as described in Attachment G: Explant and Revision Protocol, to be examined for wear and damage.
Time frame: Through Study Completion an Average of 10 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.